Clinical trial reveals increased mortality when targeting normal haematocrit in cardiac disease, highlighting risks of high haemoglobin goals.
Medicine is the science of probability, and the art of positive benefit not be achieved even if the study were allowed to continue, but more concerningly the interim uncertainty-Sir William Osler results suggested there may be a borderline higher mortality in the group of patients aiming for a normal
No takes yet. Share an insight, caveat, or question.
I Macdougal (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: